Abbott Laboratories

ABT

US0028241000

Medical Equipment, Supplies & Distribution

Market Closed - Nyse Other stock markets 01:30:24 06/07/2024 am IST			5-day change	1st Jan Change
104 ^USD	+1.65%		+0.11%	-5.50%

02/07	Evercore ISI Adjusts Price Target on Abbott Laboratories to $120 From $125, Maintains Outperform Rating	MT
01/07	Abbott Laboratories(NYSE:ABT) dropped from Russell Top 200 Growth Index	CI

Abbott Laboratories(NYSE:ABT) dropped from Russell Top 200 Growth Index

July 01, 2024

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	DOW JONES INDUSTRIAL	39,376 PTS	+0.17%	+0.66%	-
	ABBOTT LABORATORIES	104 USD	+1.65%	+0.11%	181B

Latest news about Abbott Laboratories

Evercore ISI Adjusts Price Target on Abbott Laboratories to $120 From $125, Maintains Outperform Rating	02/07	MT
Abbott Laboratories(NYSE:ABT) dropped from Russell Top 200 Growth Index	01/07	CI
Abbott Laboratories(NYSE:ABT) dropped from Russell 3000 Growth Index	01/07	CI
Abbott Laboratories(NYSE:ABT) dropped from Russell 3000E Growth Index	01/07	CI
Abbott Laboratories(NYSE:ABT) dropped from Russell 1000 Growth Index	01/07	CI
Abbott Laboratories(NYSE:ABT) dropped from Russell 1000 Growth-Defensive Index	01/07	CI
Abbott Teams Up with the National Association of Community Health Centers to Expand Access to Nutritious Food and Improve Health	20/06	CI
Abbott Laboratories Keeps Quarterly Dividend at $0.55 Per Share, Payable on Aug.15 to Shareholders of Record on July 15	14/06	MT
Abbott Laboratories Declares Quarterly Common Dividend, Payable on August 15, 2024	14/06	CI
Abbott Laboratories Says US FDA Approved 2 Over-The-Counter Continuous Glucose Monitoring Wearable Systems	10/06	MT
US FDA clears Abbott's continuous glucose monitors for over-the-counter use	10/06	RE
Abbott Receives U.S. FDA Clearance for Two New Over-The-Counter Continuous Glucose Monitoring Systems	10/06	CI
U.S. FDA set to reorganize its food division starting October	30/05	RE
Redburn Adjusts Price Target on Abbott Laboratories to $113 From $115	30/05	MT
Medtronic beats quarterly profit estimates on medical devices strength	23/05	RE
Citigroup Adjusts Price Target on Abbott Laboratories to $119 From $128, Keeps Buy Rating	22/05	MT
Abbott Laboratories Recalling HeartMate 3 Left Ventricular Assist System Implant Kit	15/05	MT
Drugmaker Abbott India posts Q4 profit rise on higher sales	09/05	RE
Abbott Laboratories Insider Sold Shares Worth $2,428,119, According to a Recent SEC Filing	09/05	MT
Tranche Update on Abbott Laboratories's Equity Buyback Plan announced on December 10, 2021.	03/05	CI
Abbott Laboratories Announces Retirement of Robert E. Funck, Jr as Executive Vice President, Finance, Effective July 1, 2024	02/05	CI
Abbott's Dissolving Stent Gets FDA Approval For Arteries Below the Knee	29/04	MT
Dexcom's profit beats estimates on strong glucose monitor demand	26/04	RE
Edwards Lifesciences first-quarter profit beats estimates on heart devices strength	26/04	RE
Daiwa Securities Trims Abbott Laboratories Price Target to $125 From $126	23/04	MT

Abbott Laboratories specializes in the research, development, manufacturing and marketing of pharmaceutical and medical products. Net sales break down by family of products as follows: - diagnostic systems and instruments (39.1%); - vascular devices (24.7%): endoprosthetic systems, dilation catheters, arterial closures, etc.; - nutrition products (12.1%): pediatric nutrition products, nutritional supplements, and dietetic products; - medicine (8.2%): anesthetics, antiviral products, antibiotics, inhibitors, anti-inflammatories, etc.; - other (15.9%). Net sales are distributed geographically as follows: the United States (38.5%), Germany (5.8%), China (5.6%), India (4.4%), Switzerland (4.1%), Japan (3.8%), Netherlands (2.7%) and others (35.1%).

Sector

Medical Equipment, Supplies & Distribution

Calendar

15/07/2024 - Détachement de

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Abbott Laboratories

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

104 USD

Average target price

124.9 USD

Spread / Average Target

+20.09%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
ABBOTT LABORATORIES	-5.50%	181B
MEDTRONIC PLC	-5.79%	99.52B
BECTON, DICKINSON AND COMPANY	-6.59%	65.82B
DEXCOM, INC.	-8.38%	45.21B
CENCORA, INC.	+8.42%	43.85B
HOYA CORPORATION	+10.10%	42.17B
METTLER-TOLEDO INTERNATIONAL, INC.	+10.97%	28.75B
TERUMO CORPORATION	+18.89%	25.39B
WEST PHARMACEUTICAL SERVICES, INC.	-8.39%	23.5B
ZIMMER BIOMET HOLDINGS, INC.	-11.25%	22.22B

Other Medical Equipment, Supplies & Distribution